Probe Scientific's MicroEye device:
This article was originally published in Clinica
UK firm Probe Scientific says that its minimally-invasive device will allow for continuous blood sampling at a patient's bedside, while avoiding the need for repeated needle punctures. The single-use MicroEye device is designed to sit inside the intravenous catheters that are already fitted to the back of the hand or lower arm of many hospitalised patients to enable medical staff to administer fluids and take blood samples simultaneously. It relies on a semi-permeable membrane being in contact with a patient's biological fluid and, by dialysis, extracting certain key indicator molecules from the fluid for continuous analysis at the bedside. The Bedford-based company plans to initiate the regulatory work to take the product to the US.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.